甲状腺微小乳头状癌中央区淋巴结转移风险评估的研究进展

doi:10.13418/j.issn.1001-165x.2021.05.024

摘要/Abstract

中图分类号:

R736.1

武元元, 　王军 . 甲状腺微小乳头状癌中央区淋巴结转移风险评估的研究进展[J]. 中国临床解剖学杂志, 2021, 39(5): 624-626.

Wu Yuanyuan, Wang Jun. Research progresson on risk assessment for central lymph node metastases in papillary thyroid microcarcinoma[J]. Chinese Journal of Clinical Anatomy, 2021, 39(5): 624-626.

参考文献 41

[1]	Hedinger CE. Histological typing of thyroid tumors. 2nd ed[M]. Berlin: Springer-Verlag, 1988.
[2]	Stewart BW, Wild CP. International agency for research on cancer (IARC)[C]// Lyon: World Cancer Report 2014.
[3]	Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133. DOI: 10.1089/thy.2015.0020.
[4]	Gao M, Ge MH, Ji QH, et al. 2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma[J]. Cancer Biol Med, 2017, 14(3): 203-211. DOI: 10.20892/j.issn.2095-3941.2017.0051.
[5]	Robbins KT, Medina JE, Wolfe GT, et a1. Standardizing neck dissection terminology. Official report of the Academy’s Committee for Head and Neck Surgery and Oncology[J]. Arch Otolaryngol Head Neck Surg, 1991, 117(6): 601-605. DOI: 10.1001/archotol.1991.01870180037007.
[6]	American Thyroid Association Surgery Working Group, American Association of Endocrine Surgeons, American Academy of Otolaryngology-Head and Neck SurgeryCarty SE, et a1. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer[J]. Thyroid, 2009, 19(11): 1153-1158. DOI: 10.1089/thy.2009.0159.
[7]	中华医学会内分泌学分会, 中华医学会外科学分会内分泌学组, 中国抗癌协会头颈肿瘤专业委员会, 等. 甲状腺结节和分化型甲状腺癌诊治指南[J]. 中华内分泌代谢杂志, 2012, 28(10): 779-797. DOI: 10.3760/cma.j.issn.1000-6699.2012.10.002.
[8]	汪菁, 王圣应. 中央区的界定及细化在甲状腺癌治疗中的意义[J]. 中华耳鼻咽喉头颈外科杂志, 2018, 53(4): 312-316. DOI: 10.3760/cma.j.issn.1673-0860.2018.04.016.
[9]	Li M, Zhu XY, Lv J, et al. Risk factors for predicting central lymph node metastasis in papillary thyroid microcarcinoma (cN0): a study of 273 resections[J]. Eur Rev Med Pharmacol Sci, 2017, 21(17): 3801-3807. PMID: 28975988.
[10]	Yuan JR, Li JH, Chen XY, et al. Identification of risk factors of central lymph node metastasis and evaluation of the effect of prophylactic central neck dissection on migration of staging and risk stratification in patients with clinically node-negative papillary thyroid microcarcinoma[J]. Bull Cancer, 2017, 104(6): 516-523. DOI: 10.1016/j.bulcan.2017.03.005.
[11]	Liu ZM, Wang LQ, Yi PF, et al. Risk factors for central lymph node metastasis of patients with papillary thyroid microcarcinoma: a meta-analysis[J]. Int J Clin Exp Pathol, 2014, 7(3): 932-937. PMID: 24696711.
[12]	Qu N, Zhang L, Ji QH, et al. Risk factors for central compartment lymph node metastasis in papillary thyroid microcarcinoma: a meta-analysis[J]. World J Surg, 2015, 39(10): 2459-2470. DOI: 10.1007/s00268-015-3108-3.
[13]	武元元, 刘锐锋, 范向达, 等. cN0期甲状腺乳头状微小癌中央区淋巴结转移危险因素的Meta分析[J]. 中国医学文摘耳鼻咽喉科学, 2020, 35(1): 2, 12-17. DOI: 10.19617/j.issn1001-1307.2020.01.004.
[14]	Cheng F, Chen YY, Zhu L, et al. Risk factors for cervical lymph node metastasis of papillary thyroid microcarcinoma: a single-center retrospective study[J]. Int J Endocrinol, 2019, 2019: 8579828. DOI: 10.1155/2019/8579828.
[15]	Oh HS, Park S, Kim M, et al. Young age and mal sex can are predictors of large-volume central neck lymph node metastasis in clinical N0 papillary thyroid microcarcinomas[J]. Thyroid, 2017, 27(10): 1285-1290. DOI: 10.1089/thy.2017.0250.
[16]	Ito Y, Miyauchi A, Kihara M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation[J]. Thyroid, 2014, 24(1): 27-34. DOI: 10.1089/thy.2013.0367.
[17]	Zhang Q, Wang ZM, Meng XY, et al. Predictors for central lymph node metastases in cN0 papillary thyroid microcarcinoma (mPTC): a retrospect analysis of 1304 cases[J]. Asian J Surg, 2019, 42(4): 571-576. DOI: 10.1016/j.asjsur.2018.08.013.
[18]	武元元, 范向达, 王军, 等. cN0期甲状腺乳头状微小癌大容量中央区淋巴结转移的危险因素[J]. 中国普通外科杂志, 2019, 28(11): 1361-1366. DOI: 10.7659/j.issn.1005-6947.2019.11.007.
[19]	Lee KJ, Cho YJ, Kim SJ, et al. Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7-mm tumor size[J]. World J Surg, 2011, 35(2): 318-323. DOI: 10.1007/s00268-010-0886-5.
[20]	王朝晖, 张悦嘉, 伏桂明, 等. 甲状腺微小乳头状癌中央区淋巴转移的危险因素分析[J]. 中华耳鼻咽喉头颈外科杂志, 2019, 54(1): 12-17. DOI: 10.3760/cma.j.issn.1673-0860.2019.01.004.
[21]	Ozden S, Er S, Saylam B, et al. A comparison of logistic regression and artificial neural networks in predicting central lymph node metastases in papillary thyroid microcarcinoma[J]. Ann Ital Chir, 2018, 89: 193-198. PMID: 30588918.
[22]	沈文亮, 黑虎, 龚文博, 等. 甲状腺微小乳头状癌中央区淋巴结转移相关因素分析[J]. 中华内分泌外科杂志, 2018, 12(1): 30-33. DOI: 10.3760/cma.j.issn.1674-6090.2018.01.008.
[23]	Luo Y, Zhao Y, Chen K, et al. Clinical analysis of cervical lymph node metastasis risk factors in patients with papillary thyroid microcarcinoma[J]. J Endocrinol Invest, 2019, 42(2): 227-236. DOI: 10.1007/s40618-018-0908-y.
[24]	Zheng XQ, Peng C, Gao M, et al. Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1587 patients[J]. Cancer Biology Medicine, 2019, 16(1): 121-130. DOI: 10.20892/j.issn.2095-3941.2018.0125.
[25]	Lombardi CP, Bellantone R, De Crea C, et al. Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area[J]. World J Surg, 2010, 34(6): 1214-1221. DOI: 10.1007/s00268-009-0375-x.
[26]	Zhou YL, Gao EL, Zhang W, et al. Factors predictive of papillary thyroid microcarcinoma with bilateral involvement and central lymph node metastasis: a retrospective study[J]. World J Surg Oncol, 2012, 10: 67. DOI: 10.1186/1477-7819-10-67.
[27]	Cai FY, Wang QX, Ni CJ, et al. A scoring system is an effective tool for predicting central lymph node metastasis in papillary thyroid microcarcinoma: a case-control study[J]. World J Surg Oncol, 2016, 14(1): 45. DOI: 10.1186/s12957-016-0808-6.
[28]	Jin WX, Ye DR, Sun YH, et al. Prediction of central lymph node metastasis in papillary thyroid microcarcinoma according to clinicopathologic factors and thyroid nodule sonographic features: a case-control study[J]. Cancer Manag Res, 2018, 10: 3237-3243. DOI: 10.2147/CMAR.S169741.
[29]	Zhou CX, Li JB, Wang Y, et al. Association of BRAF gene and TSHR with cervical lymph node metastasis of papillary thyroid microcarcinoma[J]. Oncol Lett, 2019, 17(1): 183-194. DOI: 10.3892/ol.2018.9572.
[30]	Ren HY, Shen YF, Hu DX, et al. Co-existence of BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis[J]. Cancer Manag Res, 2018, 10: 1005-1013. DOI: 10.2147/CMAR.S159583.
[31]	Khokhar MT, Day KM, Sangal RB, et al. Preoperative high-resolution ultrasound for the assessment of malignant central compartment lymph nodes in papillary thyroid cancer[J]. Thyroid, 2015, 25(12): 1351-1354. DOI: 10.1089/thy.2015.0176.
[32]	Ito Y, Tomoda C, Uruno T, et al. Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid[J]. World J Surg, 2006, 30(1): 91-99. DOI: 10.1007/s00268-005-0113-y.
[33]	Cho SJ, Suh CH, Baek JH, et al. Diagnostic performance of CT in detection of metastatic cervical lymph nodes in patients with thyroid cancer: a systematic review and meta- analysis[J]. Eur Radiol, 2019, 29(9): 4635-4647. DOI: 10.1007/s00330-019-06036-8.
[34]	Lee DH, Kim YK, Yu HW, et al. Computed tomography (CT) for detecting cervical lymph node metastasis in patients who have papillary thyroid microcarcinoma with tumor characteristics appropriate for active surveillance[J]. Thyroid, 2019, 29(11): 1653-1659. DOI: 10.1089/thy.2019.0100.
[35]	Lee Y, Kim JH, Baek JH, et al. Value of CT added to ultrasonography for the diagnosis of lymph node metastasis in patients with thyroid cancer[J]. Head Neck, 2018, 40(10): 2137-2148. DOI: 10.1002/hed.25202.
[36]	马文卿, 周平, 梁永平, 等. 甲状腺微小乳头状癌中央区颈部淋巴结转移风险评分系统的初步构建[J]. 中国普通外科杂志, 2018, 27(6): 752-760. DOI: 10.3978/j.issn.1005-6947.2018.06.015.
[37]	Xiang YY, Lin KL, Dong SY, et al. Prediction of central lymph node metastasis in 392 patients with cervical lymph node-negative papillary thyroid carcinoma in Eastern China[J]. Oncol Lett, 2015, 10(4): 2559-2564. DOI: 10.3892/ol.2015.3544.
[38]	Xu JM, Xu HX, Li XL, et al. A risk model for predicting central lymph node metastasis of papillary thyroid microcarcinoma including conventional ultrasound and acoustic radiation force impulse elastography[J]. Medicine (Baltimore), 2016, 95(3): e2558. DOI: 10.1097/MD.0000000000002558.
[39]	Lin DZ, Qu N, Shi RL, et al. Risk prediction and clinical model building for lymph node metastasis in papillary thyroid microcarcinoma[J]. Onco Targets Ther, 2016, 9: 5307-5316. DOI: 10.2147/OTT.S107913.
[40]	Wang YJ, Guan Q, Xiang J. et al. Nomogram for predicting central lymph nodemetastasis in papillary thyroid microcarcinoma: a retrospective cohort study of 8668 patients[J]. Int J Surg, 2018, 55(5): 98-102. DOI: 10.1016/j.ijsu.2018.05.023.
[41]	武元元, 王军, 毛爱红, 等. 甲状腺乳头状癌中央区淋巴结转移评分系统的建立及验证[J]. 中国癌症防治杂志, 2019, 11(6): 498-502. DOI: 10.3969/j.issn.1674-5671.2019.06.09.

甲状腺微小乳头状癌中央区淋巴结转移风险评估的研究进展

Research progresson on risk assessment for central lymph node metastases in papillary thyroid microcarcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 41

相关文章 4

Metrics

本文评价

推荐阅读 0

[1]	段方方, 侯小霞, 周寒丽, 陈露, 王留晏, 赵晓丽, 张玉洁, 孔天东. miR-133-3p对甲状腺癌SW579细胞生物学行为和移植瘤生长的影响[J]. 中国临床解剖学杂志, 2023, 41(1): 51-57.
[2]	冯成军, 周艳萌, 田应娟. 基于Nrf2/ARE信号通路探讨白藜芦醇治疗非酒精性脂肪性肝炎大鼠的作用机制[J]. 中国临床解剖学杂志, 2021, 39(5): 579-585.
[3]	吴闽, 侯慧珍, 司廷林. 过表达miR-138抑制TCF-4对甲状腺癌细胞CAL-62增殖，凋亡和运动的调节作用[J]. 中国临床解剖学杂志, 2019, 37(4): 425-430.
[4]	谭灿亮, 刘立新. microRNA参与甲状腺癌发生过程的相关机制研究进展[J]. 中国临床解剖学杂志, 2014, 32(6): 744-746.